531 related articles for article (PubMed ID: 31832202)
1. Janus kinase inhibitors for the treatment of rheumatoid arthritis demonstrate similar profiles of in vitro cytokine receptor inhibition.
Dowty ME; Lin TH; Jesson MI; Hegen M; Martin DA; Katkade V; Menon S; Telliez JB
Pharmacol Res Perspect; 2019 Dec; 7(6):e00537. PubMed ID: 31832202
[TBL] [Abstract][Full Text] [Related]
2. JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib.
Traves PG; Murray B; Campigotto F; Galien R; Meng A; Di Paolo JA
Ann Rheum Dis; 2021 Jul; 80(7):865-875. PubMed ID: 33741556
[TBL] [Abstract][Full Text] [Related]
3. Comparative efficacy and safety of tofacitinib, baricitinib, upadacitinib, filgotinib and peficitinib as monotherapy for active rheumatoid arthritis.
Ho Lee Y; Gyu Song G
J Clin Pharm Ther; 2020 Aug; 45(4):674-681. PubMed ID: 32495356
[TBL] [Abstract][Full Text] [Related]
4. Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations.
McInnes IB; Byers NL; Higgs RE; Lee J; Macias WL; Na S; Ortmann RA; Rocha G; Rooney TP; Wehrman T; Zhang X; Zuckerman SH; Taylor PC
Arthritis Res Ther; 2019 Aug; 21(1):183. PubMed ID: 31375130
[TBL] [Abstract][Full Text] [Related]
5. Janus Kinase Inhibitors Differentially Inhibit Specific Cytokine Signals in the Mesenteric Lymph Node Cells of Inflammatory Bowel Disease Patients.
Hindmarch DC; Malashanka S; Shows DM; Clarke AS; Lord JD
J Crohns Colitis; 2024 Apr; 18(4):628-637. PubMed ID: 37855324
[TBL] [Abstract][Full Text] [Related]
6. Clinical efficacy of new JAK inhibitors under development. Just more of the same?
Westhovens R
Rheumatology (Oxford); 2019 Feb; 58(Suppl 1):i27-i33. PubMed ID: 30806706
[TBL] [Abstract][Full Text] [Related]
7. Comparative Efficacy of JAK Inhibitors for Moderate-To-Severe Rheumatoid Arthritis: A Network Meta-Analysis.
Pope J; Sawant R; Tundia N; Du EX; Qi CZ; Song Y; Tang P; Betts KA
Adv Ther; 2020 May; 37(5):2356-2372. PubMed ID: 32297280
[TBL] [Abstract][Full Text] [Related]
8. Recent Progress in JAK Inhibitors for the Treatment of Rheumatoid Arthritis.
Nakayamada S; Kubo S; Iwata S; Tanaka Y
BioDrugs; 2016 Oct; 30(5):407-419. PubMed ID: 27577235
[TBL] [Abstract][Full Text] [Related]
9. Clinical efficacy of launched JAK inhibitors in rheumatoid arthritis.
Taylor PC
Rheumatology (Oxford); 2019 Feb; 58(Suppl 1):i17-i26. PubMed ID: 30806707
[TBL] [Abstract][Full Text] [Related]
10. JAK inhibitors impair GM-CSF-mediated signaling in innate immune cells.
Fujita Y; Matsuoka N; Temmoku J; Furuya-Yashiro M; Asano T; Sato S; Matsumoto H; Watanabe H; Kozuru H; Yatsuhashi H; Kawakami A; Migita K
BMC Immunol; 2020 Jun; 21(1):35. PubMed ID: 32539713
[TBL] [Abstract][Full Text] [Related]
11. Clinical significance of Janus Kinase inhibitor selectivity.
Choy EH
Rheumatology (Oxford); 2019 Jun; 58(6):953-962. PubMed ID: 30508136
[TBL] [Abstract][Full Text] [Related]
12. Adverse events, clinical considerations and management recommendations in rheumatoid arthritis patients treated with JAK inhibitors.
Atzeni F; Talotta R; Nucera V; Marino F; Gerratana E; Sangari D; Masala IF; Sarzi-Puttini P
Expert Rev Clin Immunol; 2018 Nov; 14(11):945-956. PubMed ID: 30058434
[TBL] [Abstract][Full Text] [Related]
13. Tofacitinib Suppresses Several JAK-STAT Pathways in Rheumatoid Arthritis
Palmroth M; Kuuliala K; Peltomaa R; Virtanen A; Kuuliala A; Kurttila A; Kinnunen A; Leirisalo-Repo M; Silvennoinen O; Isomäki P
Front Immunol; 2021; 12():738481. PubMed ID: 34630419
[TBL] [Abstract][Full Text] [Related]
14. Early phase studies of JAK1 selective inhibitors in rheumatoid arthritis.
Avci AB; Feist E; Burmester GR
Rheumatology (Oxford); 2021 May; 60(Suppl 2):ii11-ii16. PubMed ID: 33950228
[TBL] [Abstract][Full Text] [Related]
15. Janus kinase inhibitors for atopic dermatitis: a promising treatment modality.
Cartron AM; Nguyen TH; Roh YS; Kwatra MM; Kwatra SG
Clin Exp Dermatol; 2021 Jul; 46(5):820-824. PubMed ID: 33484582
[TBL] [Abstract][Full Text] [Related]
16. Progress in understanding the safety and efficacy of Janus kinase inhibitors for treatment of rheumatoid arthritis.
Iwata S; Tanaka Y
Expert Rev Clin Immunol; 2016 Oct; 12(10):1047-57. PubMed ID: 27253519
[TBL] [Abstract][Full Text] [Related]
17. Relative efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib in comparison to adalimumab in patients with active rheumatoid arthritis.
Lee YH; Song GG
Z Rheumatol; 2020 Oct; 79(8):785-796. PubMed ID: 32055928
[TBL] [Abstract][Full Text] [Related]
18. Clinical use of Jak 1 inhibitors for rheumatoid arthritis.
Nash P
Rheumatology (Oxford); 2021 May; 60(Suppl 2):ii31-ii38. PubMed ID: 33950231
[TBL] [Abstract][Full Text] [Related]
19. A novel treatment for psoriatic arthritis: Janus kinase inhibitors.
Chen M; Dai SM
Chin Med J (Engl); 2020 Apr; 133(8):959-967. PubMed ID: 32209886
[TBL] [Abstract][Full Text] [Related]
20. Comparative efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib in active rheumatoid arthritis refractory to biologic disease-modifying antirheumatic drugs.
Lee YH; Song GG
Z Rheumatol; 2021 May; 80(4):379-392. PubMed ID: 32367211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]